01
March
2023
|
07:59 AM
Europe/Amsterdam
Big News for Japan’s Health Ministry!
Summary
Get the latest on Bayer’s submission of aflibercept 8 mg for marketing authorization in Japan. The submission is based upon the favorable outcomes of stage III scientific trials, PULSAR and PHOTON, in which aflibercept 8 mg showed unmatched results against comparable treatments. Read further details here.